M
Biopharmaceutical company developing antibody-based therapeutics for cancer and autoimmune diseases.
About
MacroGenics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative antibody-based therapeutics for cancer, autoimmune disorders, and infectious diseases. They leverage proprietary technology platforms like DART® and Trident™ to create bispecific and trispecific antibodies that target multiple antigens or cells, aiming to enhance the immune system's ability to fight disease. The company has a pipeline of product candidates and strategic collaborations with global pharmaceutical companies.
Tags
Performance
Company Timeline
No timeline data for this period
Score Breakdown
28Traction
36Team
70Visibility
2Profile
55Community
0Discussion (0)
Join the discussion
No comments yet. Be the first to share your thoughts!
Frequently Asked Questions
What does MacroGenics do?
MacroGenics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative antibody-based therapeutics for cancer, autoimmune disorders, and infectious diseases. They leverage proprietary technology platforms like DART® and Trident™ to create bispecific and trispecific antibodies that target multiple antigens or cells, aiming to enhance the immune system's ability to fight disease. The company has a pipeline of product candidates and strategic collaborations with…
How much funding has MacroGenics raised?
MacroGenics has raised a total of $14M in funding. The most recent round on record is Series A.
Where is MacroGenics headquartered?
MacroGenics is headquartered in Rockville, United States.
When was MacroGenics founded?
MacroGenics was founded in 2000.
What industry does MacroGenics operate in?
MacroGenics operates in Biotech, MedTech, HealthTech, Genomics, Drug Discovery, Clinical Trials.
What is MacroGenics's current status?
MacroGenics's current operating status is: Public.